Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component parts into either the blood or urine, hence called non-secretory myeloma. Some non-secretory myeloma patients may produce the immunoglobulin proteins but they have defects in secretion. Due to lack of these protein biomarkers in blood and urine, it may be difficult to assess and treat the disease. Our myeloma panel is talking to Dr. Frits Van Rhee about latest developments and new options available in assessment and treatment of nonsecretory myeloma. Listen to podcast.
- Conway Cyclist Joins UAMS Myeloma Institute Team to Honor Dad
- Myeloma Institute Hosts Patient Power Event on Rare Blood Diseases
- Evolutionary biology of high-risk multiple myeloma
- UAMS Myeloma Institute Welcomes Patient Power to Little Rock Campus for Free Educational Event on the Rare Blood Cancer
- Don’t Fear the Gear